Literature DB >> 19179906

Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates.

Obondent Mauricio1, Lisa Francis, Uzma Athar, Chirag Shah, Madhuchhanda Chaudhary, Ajeet Gajra.   

Abstract

Hypertrophic osteoarthropathy (HOA) is characterized by clubbing of digits and, in more advanced stages, by periosteal new bone formation and synovial effusions. Secondary HOA typically occurs in the setting of intrathoracic malignancy, infections or lung metastases. We report a case with an atypical presentation of HOA. The prominent systemic signs, presentation limited to lower extremities only and an excellent response to bisphosphonates make this case unusual.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179906     DOI: 10.1097/JTO.0b013e3181952915

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  5 in total

1.  Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium.

Authors:  Sebastian G Bernardo; Jason J Emer; Mark E Burnett; Marsha Gordon
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

Review 2.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 3.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980

4.  A complicated case of pachydermoperiostosis with spondyloarthritides: a case report.

Authors:  Qing Zhang; Min Shen; Bo Yang; Keyi Yu
Journal:  J Med Case Rep       Date:  2013-12-13

Review 5.  Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literature.

Authors:  Francesco Bozzao; Stella Bernardi; Franca Dore; Lorenzo Zandonà; Fabio Fischetti
Journal:  BMC Musculoskelet Disord       Date:  2018-05-14       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.